|
US5574205A
(en)
|
1989-07-25 |
1996-11-12 |
Cell Genesys |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
PT772624E
(pt)
|
1994-04-06 |
2001-03-30 |
Immunex Corp |
Interleucina-15
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
ATE427318T1
(de)
|
2000-09-14 |
2009-04-15 |
Beth Israel Hospital |
Modulierung von il-2 und il-15 vermittelten t zellantworten
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20040225112A1
(en)
|
2003-05-06 |
2004-11-11 |
Crew Mark D. |
Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
DE602005016683D1
(de)
|
2004-07-10 |
2009-10-29 |
Fox Chase Cancer Ct |
Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
|
|
US20060046294A1
(en)
|
2004-08-26 |
2006-03-02 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Site-specific recombination systems for use in eukaryotic cells
|
|
AU2005336093B2
(en)
|
2004-10-08 |
2011-02-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Adoptive immunotherapy with enhanced T lymphocyte survival
|
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
ｓｃ（Ｆｖ）２構造異性体
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US8846395B2
(en)
|
2005-06-01 |
2014-09-30 |
Wisconsin Alumni Research Foundation |
Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
GB0523954D0
(en)
|
2005-11-24 |
2006-01-04 |
Ucb Celltech |
Bioassays
|
|
ATE513034T1
(de)
|
2005-12-16 |
2011-07-15 |
Ribovax Biotechnologies Sa |
Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen
|
|
EP2366787B1
(en)
|
2006-01-13 |
2019-12-11 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
|
|
US8946385B2
(en)
|
2007-01-30 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor
|
|
WO2008102199A1
(en)
|
2007-02-20 |
2008-08-28 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
DK2160401T3
(da)
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusionsmolekyler og il-15-varianter
|
|
KR100902340B1
(ko)
|
2007-08-02 |
2009-06-12 |
한국생명공학연구원 |
Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
|
|
US8530636B2
(en)
|
2008-05-07 |
2013-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for regulating protein function in cells in vivo using synthetic small molecules
|
|
EP3279314A1
(en)
|
2008-06-04 |
2018-02-07 |
Cellular Dynamics International, Inc. |
Methods for the production of ips cells using non-viral approach
|
|
EP3231869A1
(en)
|
2008-06-13 |
2017-10-18 |
Whitehead Institute for Biomedical Research |
Programming and reprogramming of cells
|
|
JP5652783B2
(ja)
|
2008-09-08 |
2015-01-14 |
独立行政法人理化学研究所 |
ＮＫＴ細胞由来ｉＰＳ細胞およびそれ由来のＮＫＴ細胞
|
|
JP5756017B2
(ja)
|
2008-11-07 |
2015-07-29 |
サニーブルック ヘルス サイエンシズ センター |
ヒト前駆ｔ細胞
|
|
KR101720961B1
(ko)
|
2009-02-27 |
2017-03-29 |
셀룰러 다이내믹스 인터내셔널, 인코포레이티드 |
다능성 세포의 분화
|
|
CA2755686A1
(en)
|
2009-03-16 |
2010-09-23 |
Daniel A. Vallera |
Methods and compositions for bi-specific targeting of cd19/cd22
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
DK2496698T3
(en)
|
2009-11-03 |
2019-04-15 |
Hope City |
TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
|
|
MX346912B
(es)
|
2009-12-07 |
2017-04-05 |
Univ Leland Stanford Junior |
Metodos para mejorar terapia con anticuerpos antitumor.
|
|
HUE041436T2
(hu)
|
2009-12-10 |
2019-05-28 |
Univ Minnesota |
Tal-effektor-közvetített DNS-módosítás
|
|
US9206394B2
(en)
|
2010-02-03 |
2015-12-08 |
The University Of Tokyo |
Method for reconstructing immune function using pluripotent stem cells
|
|
WO2012018933A2
(en)
|
2010-08-04 |
2012-02-09 |
Cellular Dynamics International, Inc. |
Reprogramming immortalized b cells
|
|
CN107880136B
(zh)
|
2010-09-21 |
2021-11-12 |
阿尔托生物科学有限公司 |
多聚体il-15可溶性融合分子与其制造与使用方法
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012109208A2
(en)
|
2011-02-08 |
2012-08-16 |
Cellular Dynamics International, Inc. |
Hematopoietic precursor cell production by programming
|
|
EP2694549B1
(en)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
WO2012145384A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
WO2013059593A1
(en)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
CA2861031C
(en)
|
2012-02-03 |
2022-10-25 |
Carole BOURQUIN |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
GB201206559D0
(en)
|
2012-04-13 |
2012-05-30 |
Ucl Business Plc |
Polypeptide
|
|
US20150056225A1
(en)
|
2012-04-17 |
2015-02-26 |
University Of Washington Through Its Center For Commercialization |
HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
LT4461308T
(lt)
|
2012-07-13 |
2025-06-10 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo valdymas
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
WO2015142314A1
(en)
|
2013-03-15 |
2015-09-24 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
AU2014248119B2
(en)
|
2013-04-03 |
2019-06-20 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
|
|
CA2909733C
(en)
|
2013-04-18 |
2023-10-17 |
Fondazione Telethon |
Effective delivery of large genes by dual aav vectors
|
|
EP3415534A1
(en)
|
2013-05-10 |
2018-12-19 |
Numab Therapeutics AG |
Bispecific constructs and their use in the treatment of various diseases
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
CA2912172A1
(en)
|
2013-06-05 |
2014-12-11 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
|
EP3048112B1
(en)
|
2013-09-18 |
2020-03-11 |
Tosoh Corporation |
Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
US20160333108A1
(en)
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
ES3063961T3
(en)
|
2014-02-14 |
2026-04-21 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CN113699159A
(zh)
|
2014-03-28 |
2021-11-26 |
明尼苏达大学评议会 |
涉及经工程改造的cd16的多肽、细胞和方法
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
KR102654784B1
(ko)
|
2014-07-18 |
2024-04-04 |
사이아스 가부시키가이샤 |
다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법
|
|
US10519248B2
(en)
|
2014-07-25 |
2019-12-31 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
TWI542139B
(zh)
|
2014-07-31 |
2016-07-11 |
瑞昱半導體股份有限公司 |
數位預失真電路與方法以及數位預失真訓練電路
|
|
CN107002084B
(zh)
|
2014-09-19 |
2021-09-10 |
希望之城公司 |
靶向IL13Rα2的共刺激嵌合抗原受体T细胞
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
ES2904301T3
(es)
|
2014-11-03 |
2022-04-04 |
Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum |
Receptores de células T dirigidos contra Bob1 y usos de los mismos
|
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
|
US10975392B2
(en)
|
2014-12-05 |
2021-04-13 |
Abcam Plc |
Site-directed CRISPR/recombinase compositions and methods of integrating transgenes
|
|
CA2966234A1
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
US9765330B1
(en)
|
2015-01-09 |
2017-09-19 |
Nant Holdings Ip, Llc |
Compositions and methods for reduction of allograft recognition and rejection
|
|
DK3268480T3
(da)
|
2015-03-09 |
2021-07-26 |
Sinai Health Sys |
Værktøjer og fremgangsmåder til anvendelse af celledelingsloci til at styre celleproliferation
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
IL287051B
(en)
|
2015-03-27 |
2022-09-01 |
Immunitybio Inc |
nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
PT3294764T
(pt)
|
2015-05-15 |
2021-02-15 |
Hope City |
Composições de recetores de antigénios quiméricos
|
|
CN108137669B
(zh)
|
2015-05-18 |
2023-02-17 |
优瑞科生物技术公司 |
抗ror1嵌合抗原受体
|
|
US10639329B2
(en)
|
2015-06-12 |
2020-05-05 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
|
JP6403277B2
(ja)
|
2015-06-30 |
2018-10-10 |
オートモーティブエナジーサプライ株式会社 |
リチウムイオン二次電池の製造方法
|
|
EP4043556B1
(en)
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
ES2970269T3
(es)
|
2015-07-29 |
2024-05-27 |
Onk Therapeutics Ltd |
Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
WO2017040945A1
(en)
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
SG11201802912PA
(en)
|
2015-10-10 |
2018-05-30 |
Intrexon Corp |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
CN108431211B
(zh)
|
2015-10-20 |
2026-03-24 |
富士胶片细胞动力公司 |
通过遗传编程的多谱系造血前体细胞产生
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CA3005753A1
(en)
|
2015-11-19 |
2017-06-29 |
Bloodcenter Research Foundation |
Method of manufacturing dual-specific t-cells for use in cancer immunotherapy
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
ES2952064T3
(es)
|
2015-12-16 |
2023-10-26 |
Walter & Eliza Hall Inst Medical Res |
Inhibición de la proteína SH2 inducida por citocinas en células NK
|
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
|
WO2017123559A2
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
KR102438360B1
(ko)
|
2016-03-04 |
2022-08-31 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
|
|
CN108780565B
(zh)
|
2016-03-24 |
2022-08-02 |
富士胶片株式会社 |
图像处理装置、图像处理方法及存储介质
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
CN109415687A
(zh)
|
2016-04-07 |
2019-03-01 |
蓝鸟生物公司 |
嵌合抗原受体t细胞组合物
|
|
ES2886631T3
(es)
|
2016-04-15 |
2021-12-20 |
Univ Kyoto |
Método para inducir células T positivas para CD8 específicas de antígeno
|
|
US11377637B2
(en)
|
2016-04-15 |
2022-07-05 |
Memorial Sloan Kettering Cancer Center |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
|
US12060394B2
(en)
|
2016-04-28 |
2024-08-13 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CN109476749A
(zh)
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
|
CA3000514A1
(en)
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
JP7500195B2
(ja)
|
2016-08-23 |
2024-06-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
|
|
SG11201901642XA
(en)
|
2016-08-26 |
2019-03-28 |
Baylor College Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
EP3510145A4
(en)
|
2016-09-06 |
2020-03-25 |
The Children's Medical Center Corporation |
IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
|
|
CA3035075A1
(en)
|
2016-09-23 |
2018-03-29 |
Fred Hutchinson Cancer Research Center |
Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
EP3529279A4
(en)
|
2016-10-19 |
2020-04-29 |
The Governing Council of the University of Toronto |
CD133 BINDERS AND USE THEREOF
|
|
KR102709329B1
(ko)
|
2016-10-19 |
2024-09-23 |
셀렉티스 에스.에이. |
개선된 면역 세포들 치료를 위한 타겟인 유전자 삽입
|
|
GB201619876D0
(en)
|
2016-11-24 |
2017-01-11 |
Cambridge Entpr Ltd |
Controllable transcription
|
|
WO2018108106A1
(zh)
|
2016-12-13 |
2018-06-21 |
科济生物医药（上海）有限公司 |
抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
|
|
US20200087681A1
(en)
|
2016-12-21 |
2020-03-19 |
Ucl Business Plc |
Therapeutic cells
|
|
JP2020503043A
(ja)
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
遺伝子改変されたナチュラルキラー細胞
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
CN110177869A
(zh)
|
2017-01-13 |
2019-08-27 |
加利福尼亚大学董事会 |
免疫改造的多能细胞
|
|
WO2018161038A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Il12 compositions and methods for immunotherapy
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018165913A1
(zh)
|
2017-03-15 |
2018-09-20 |
南京凯地生物科技有限公司 |
靶向nkg2dl的特异性嵌合抗原受体及其car-t细胞以及它们的应用
|
|
CN108624608B
(zh)
|
2017-03-17 |
2021-11-16 |
上海恒润达生生物科技股份有限公司 |
靶向mesothelin的第四代嵌合抗原受体的制备方法和用途
|
|
CN110637083A
(zh)
|
2017-03-20 |
2019-12-31 |
华盛顿大学 |
细胞及其使用和制备方法
|
|
EP4414380A3
(en)
|
2017-03-31 |
2024-12-04 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
WO2018191490A1
(en)
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
|
EP3635132A4
(en)
|
2017-06-07 |
2021-05-26 |
Intrexon Corporation |
EXPRESSION OF NOVEL CELL MARKERS
|
|
CA3063169A1
(en)
|
2017-06-07 |
2018-12-13 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
JP7136816B2
(ja)
|
2017-06-23 |
2022-09-13 |
インスクリプタ， インコーポレイテッド |
核酸誘導型ヌクレアーゼ
|
|
CN111432823A
(zh)
|
2017-07-25 |
2020-07-17 |
得克萨斯大学体系董事会 |
增强的嵌合抗原受体及其用途
|
|
CA3071683A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
CA3076099A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Linkers for chimeric antigen receptors
|
|
US20190091310A1
(en)
|
2017-09-26 |
2019-03-28 |
Stephen E. Wright |
Nonreleased il-12 for therapy of cancer
|
|
MX2020004185A
(es)
|
2017-09-27 |
2021-01-08 |
Univ Southern California |
Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
|
|
US20200239544A1
(en)
|
2017-10-03 |
2020-07-30 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
CN107723275B
(zh)
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
EP3720950B1
(en)
|
2017-12-05 |
2025-09-03 |
Celyad S.A. |
Reducing fratricide of immune cells expressing nkg2d-based receptors
|
|
US20210015859A1
(en)
|
2017-12-08 |
2021-01-21 |
Fate Therapeutics, Inc. |
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
WO2019118516A1
(en)
|
2017-12-11 |
2019-06-20 |
Editas Medicine, Inc. |
Cpf1-related methods and compositions for gene editing
|
|
CN111479917A
(zh)
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
|
MA51428A
(fr)
|
2017-12-22 |
2020-11-04 |
Bluebird Bio Inc |
Récepteur d'antigène chimérique multivalent
|
|
CA3083779A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
US20230158070A1
(en)
|
2018-01-30 |
2023-05-25 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CA3090791A1
(en)
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP2021514185A
(ja)
|
2018-02-14 |
2021-06-10 |
サニーブルック リサーチ インスティチュート |
Ｔ細胞系列の細胞を発生させるための方法
|
|
CN112534044A
(zh)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
|
KR102849343B1
(ko)
|
2018-03-07 |
2025-08-25 |
포세이다 테라퓨틱스, 인크. |
Cartyrin 조성물 및 사용 방법
|
|
CN110324069B
(zh)
|
2018-03-28 |
2021-02-02 |
维沃移动通信有限公司 |
波束失败处理方法、终端、网络设备及可读存储介质
|
|
JP7575271B2
(ja)
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
|
CN110343711B
(zh)
|
2018-04-04 |
2024-01-12 |
达仁生物科技有限公司 |
嵌合抗原受体和其治疗癌症的方法
|
|
WO2019204661A1
(en)
|
2018-04-18 |
2019-10-24 |
Altius Institute For Biomedical Sciences |
Methods for assessing specificity of cell engineering tools
|
|
JP2021523733A
(ja)
|
2018-04-18 |
2021-09-09 |
アルティウス インスティテュート フォー バイオメディカル サイエンスィズ |
動物病原体由来ポリペプチドおよびその遺伝子工学的利用
|
|
EP3561053A1
(en)
|
2018-04-26 |
2019-10-30 |
Baylor College of Medicine |
Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
|
|
CN108531458A
(zh)
|
2018-04-27 |
2018-09-14 |
赛诺（深圳）生物医药研究有限公司 |
治疗肿瘤的基因工程自然杀伤细胞产品
|
|
MX2020011697A
(es)
|
2018-05-03 |
2020-12-10 |
Univ Texas |
Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario.
|
|
US12227763B2
(en)
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
EP4474391A3
(en)
|
2018-05-14 |
2025-02-26 |
Indapta Therapeutics, Inc. |
Subsets of human natural killer cells with enhanced antibody-directed immune responses
|
|
AU2019269118B2
(en)
|
2018-05-15 |
2025-02-27 |
Autolus Limited |
Chimeric antigen receptor
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
US20200109364A1
(en)
|
2018-05-31 |
2020-04-09 |
Washington University |
Methods for genome-editing and activation of cells
|
|
JP2021525530A
(ja)
|
2018-06-01 |
2021-09-27 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制
|
|
US20190382759A1
(en)
|
2018-06-08 |
2019-12-19 |
Locana, Inc. |
Compositions and methods for the modulation of adaptive immunity
|
|
US20210230289A1
(en)
|
2018-06-12 |
2021-07-29 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
EP3806857A4
(en)
|
2018-06-14 |
2022-03-02 |
2seventy bio, Inc. |
CD79A CHIMERIC ANTIGEN RECEPTORS
|
|
TWI809130B
(zh)
|
2018-06-22 |
2023-07-21 |
美商凱特製藥公司 |
嵌合跨膜蛋白及其用途
|
|
US12202855B2
(en)
|
2018-06-25 |
2025-01-21 |
Peter Maccallum Cancer Institute |
Modified T cells and uses thereof
|
|
US12264181B2
(en)
|
2018-06-27 |
2025-04-01 |
Altius Institute For Biomedical Sciences |
Nucleic acid binding domains and methods of use thereof
|
|
WO2020010235A1
(en)
|
2018-07-05 |
2020-01-09 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Car t cells that target b-cell antigens
|
|
BR112021000727A2
(pt)
|
2018-07-20 |
2021-04-13 |
Surface Oncology, Inc. |
Composições anti-cd112r e métodos
|
|
CN112752838A
(zh)
|
2018-07-26 |
2021-05-04 |
国立大学法人京都大学 |
制备引入外源抗原受体的细胞的方法
|
|
CN110305847B
(zh)
|
2018-07-27 |
2021-05-18 |
赛诺生（深圳）基因产业发展有限公司 |
一种用于治疗肿瘤的基因工程细胞
|
|
WO2020028656A1
(en)
|
2018-08-01 |
2020-02-06 |
Nantkwest, Inc. |
A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US20220054544A1
(en)
|
2018-09-21 |
2022-02-24 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
|
AU2019370276A1
(en)
|
2018-10-30 |
2021-06-10 |
Board Of Regents, The University Of Texas System |
Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof
|
|
KR20240162586A
(ko)
|
2018-10-31 |
2024-11-15 |
난트퀘스트, 인크. |
Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
|
|
SG11202104524YA
(en)
*
|
2018-11-01 |
2021-05-28 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for t cell engineering
|
|
IL316887A
(en)
|
2018-11-06 |
2025-01-01 |
Immunitybio Inc |
NK-92 cells with chimeric antigen receptor modification
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CN121518401A
(zh)
|
2018-11-26 |
2026-02-13 |
免疫生物公司 |
具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
|
|
WO2020113224A2
(en)
|
2018-11-30 |
2020-06-04 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptor factories and methods of use thereof
|
|
KR102943217B1
(ko)
|
2018-12-02 |
2026-03-25 |
페이트 세러퓨틱스, 인코포레이티드 |
향상된 iPSC 유래 효과기 세포를 사용한 면역요법
|
|
US12227551B2
(en)
|
2018-12-11 |
2025-02-18 |
Obsidian Therapeutics, Inc. |
Membrane bound IL12 compositions and methods for tunable regulation
|
|
US12600760B2
(en)
|
2018-12-13 |
2026-04-14 |
The General Hospital Corporation |
Chimeric antigen receptors targeting CD79B and CD19
|
|
CN111355871A
(zh)
|
2018-12-21 |
2020-06-30 |
三赢科技（深圳）有限公司 |
镜头模组及其组装方法
|
|
CA3125302A1
(en)
|
2019-01-18 |
2020-07-23 |
University Of Southern California |
Methods and compositions to improve the safety and efficacy of cellular therapies
|
|
EP3924467A1
(en)
|
2019-02-15 |
2021-12-22 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
CA3130489A1
(en)
|
2019-02-18 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
AU2020271523A1
(en)
|
2019-04-11 |
2021-10-14 |
Fate Therapeutics, Inc. |
CD3 reconstitution in engineered iPSC and immune effector cells
|
|
US20220162301A1
(en)
|
2019-04-12 |
2022-05-26 |
PhanesTherapeutics, Inc. |
Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
|
|
WO2020212756A2
(en)
|
2019-04-18 |
2020-10-22 |
Genkin Dmitry Dmitrievich |
Reprogramming of polymorphonuclear leukocytes
|
|
EP3962527A4
(en)
|
2019-04-30 |
2023-11-01 |
Senti Biosciences, Inc. |
CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
|
|
WO2020231882A2
(en)
|
2019-05-10 |
2020-11-19 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
WO2020237227A1
(en)
|
2019-05-22 |
2020-11-26 |
Massachusetts Institute Of Technology |
Circular rna compositions and methods
|
|
JP7629414B2
(ja)
|
2019-06-04 |
2025-02-13 |
ンカルタ・インコーポレイテッド |
免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
|
|
CA3144871A1
(en)
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
US20220267802A1
(en)
|
2019-07-15 |
2022-08-25 |
President And Fellows Of Harvard College |
Methods and compositions for gene delivery
|
|
US20220251572A1
(en)
|
2019-07-23 |
2022-08-11 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
JP2022551537A
(ja)
|
2019-10-07 |
2022-12-09 |
ユニヴェルシテ デクス－マルセイユ |
ネクチン－４に対する特異性を有する抗体及びその使用
|
|
JP2022551975A
(ja)
|
2019-10-15 |
2022-12-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｆｃ封鎖を介する移植細胞保護
|
|
EP4045539A4
(en)
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
JP2022553292A
(ja)
|
2019-10-21 |
2022-12-22 |
パーデュー・リサーチ・ファウンデーション |
操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法
|
|
BR112022008215A2
(pt)
|
2019-10-31 |
2022-07-12 |
Res Inst Nationwide Childrens Hospital |
Geração de células nk humanas primárias e expandidas knock-out de cd38
|
|
WO2021092252A1
(en)
|
2019-11-05 |
2021-05-14 |
Forman Stephen J |
Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof
|
|
BR112022009137A2
(pt)
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Métodos de fabricação de células t com receptor de antígeno quimérico (car)
|
|
IL292467A
(en)
|
2019-11-13 |
2022-06-01 |
Crispr Therapeutics Ag |
Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70
|
|
WO2021099944A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
|
|
AU2020397956A1
(en)
|
2019-12-04 |
2022-07-07 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
EP4076479A4
(en)
|
2019-12-18 |
2024-05-22 |
Editas Medicine, Inc. |
GENETICALLY MODIFIED CELLS FOR THERAPY
|
|
CA3165076A1
(en)
|
2020-01-17 |
2021-07-22 |
Ryan Clarke |
Safety switches for regulation of gene expression
|
|
US20210254005A1
(en)
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
|
EP4097219A4
(en)
|
2020-01-28 |
2023-10-11 |
ImmunityBio, Inc. |
Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
EP4146813A4
(en)
|
2020-05-04 |
2024-09-04 |
Editas Medicine, Inc. |
Selection by essential-gene knock-in
|
|
WO2021234662A1
(en)
|
2020-05-21 |
2021-11-25 |
Crispr Therapeutics Ag |
Genetically engineered car t cells that secrete interleukin-12 and therapeutic uses thereof
|
|
WO2021252804A1
(en)
|
2020-06-12 |
2021-12-16 |
Nkarta, Inc. |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
AU2021292695A1
(en)
|
2020-06-19 |
2023-02-02 |
Fate Therapeutics, Inc. |
Combining iPSC-derived effector cell types for immunotherapy use
|
|
KR20230084470A
(ko)
|
2020-08-14 |
2023-06-13 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
IL301956A
(en)
|
2020-10-07 |
2023-06-01 |
Dren Bio Inc |
Antibodies against dectin-1 and methods of using them
|
|
IL301983A
(en)
|
2020-10-09 |
2023-06-01 |
Fate Therapeutics Inc |
Transgenic induced pluripotent stem cells and effector carrier cells of the immune system
|
|
WO2022087453A1
(en)
|
2020-10-22 |
2022-04-28 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
|
EP4232465A4
(en)
|
2020-10-26 |
2024-10-23 |
Memorial Sloan Kettering Cancer Center |
Cells with cd70 knockout and uses for immunotherapy
|
|
JP2023549098A
(ja)
|
2020-11-04 |
2023-11-22 |
フェイト セラピューティクス，インコーポレイティド |
固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
CN116981685A
(zh)
|
2020-12-03 |
2023-10-31 |
世纪治疗股份有限公司 |
基因工程化细胞及其用途
|
|
AR124223A1
(es)
|
2020-12-03 |
2023-03-01 |
Century Therapeutics Inc |
Células genéticamente diseñadas y usos de las mismas
|
|
MX2023011927A
(es)
|
2021-04-07 |
2023-10-23 |
Century Therapeutics Inc |
Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
|
|
WO2022216524A1
(en)
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
|
|
US20220333074A1
(en)
|
2021-04-07 |
2022-10-20 |
Century Therapeutics, Inc. |
Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
|